IFNA5

Across TCGA pan-cancer cohorts, IFNA5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IFNA5 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IFNA5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFNA5 expression acts as an unfavorable survival marker.

LIHC, SKCM, and COAD are the cancer types where IFNA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	18	view →
SKCM	DFS	Median	II,III,IV	0.163	0.688	<.001	15	view →
COAD	OS	Median	II,III,IV	0.125	0.785	.001	9	view →
LUAD	OS	Median	II,III,IV	0.017	0.678	<.001	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IFNA5–LIHC (DFS)

Open the LIHC breakdown →